There were no critical or major observations in the inspection, Lupin said in a press release.
"We are committed to maintaining truly global quality standards at our manufacturing units. The successful inspection by UK MHRA is a meaningful development for our Goa plant,” said Nilesh Gupta, Managing Director, Lupin.
On Monday, April 2, Lupin announced the successful facility review carried out by Health Canada for its Pithampur Unit 2 (Indore) manufacturing facility.
Following the review, Health Canada has maintained the compliant rating for Unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License,’ it added.
At 12:07 pm; the stock was trading 1.5% higher at Rs 787 on the BSE, against 0.21% decline in the S&P BSE Sensex. A combined 1.62 million shares changed hands on the counter on the BSE and NSE so far.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in